Investigator-Initiated Phase 1Trial of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field
of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced an agreement with Dana-Farber/Boston
Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924,
Aileron’s lead clinical candidate. In this investigator-initiated trial, pediatric patients with solid tumors will receive
ALRN-6924 as a single agent, while pediatric patients with acute leukemia will be treated with a combination of ALRN-6924 and
cytarabine. In addition to these two dose-escalation cohorts, a third cohort of this trial will be biomarker-enriched with
the intent of improving response rates with this precision medicine approach.
Principal Investigator, Steven DuBois, MD, of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, commented:
“Recently published preclinical data by Kimberly Stegmaier, MD, and Loren Walensky, MD, PhD, both from Dana-Farber/Boston
Children’s Cancer and Blood Disorders Center, revealed that targeting MDM2 and MDMX had a selective cytotoxic effect in a range of
pediatric cancers. Together with our collaborators at several world-class pediatric clinical trial sites, we are committed to
bringing this agent to the clinic for our pediatric patients with relapsed cancer.”
“I am particularly gratified to see the initiation of this trial,” said Dr. Walensky. “Dana-Farber and I have deep roots
in the discovery and development of this technology. Seeing it deployed now in an effort to treat pediatric patients
represents great progress.”
“MDMX and MDM2 play a role in many cancers, and our dual inhibitor of MDMX and MDM2, ALRN-6924, has shown in clinical trials
that it can achieve responses in cancer patients,” said Manuel Aivado, MD, PhD and CEO of Aileron Therapeutics. “We are thankful
for the opportunity to provide ALRN-6924 to relapsed and refractory pediatric patients in an effort to improve outcomes for these
children.”
About ALRN-6924
ALRN-6924 is a first-in-class, stabilized alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its
interactions with both its endogenous inhibitors, MDMX and MDM2. For p53 wild-type tumors, ALRN-6924 can restore p53-dependent
tumor suppression. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of solid and hematological
cancers, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and peripheral T-cell lymphoma (PTCL). For
information about Aileron’s clinical trials, please visit www.clinicaltrials.gov.
About Aileron
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides
that address the most important intracellular targets in oncology and other therapeutic areas. The stabilized helical structure of
our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding
properties, resulting in unique drugs like ALRN-6924. Our current focus is to improve the standard of care for patients with solid
tumors and hematological malignancies by developing safe and effective therapies that leverage our proprietary peptide platform.
For more information, visit www.aileronrx.com, and for more information about our clinical trials please visit
www.clinicaltrials.gov.
Forward-Looking Statements
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy
and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various
important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods
and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results
obtained in future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a
timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and
Drug Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval from
regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully
distributed and marketed; whether this collaboration will be successful and the Company will be able to enter into additional
collaborations; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form 10-Q for the
period ended June 30, 2018, filed on August 7, 2018, and risks described in other filings that Aileron may make with the Securities
and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and
Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future
events or otherwise.
Investors:
Aileron Therapeutics
Don Dougherty, CFO
617-995-0900
ddougherty@aileronrx.com
Hans C. Vitzthum
LifeSci Advisors, LLC.
617-535-7743
Hans@LifeSciAdvisors.com
